Knight Therapeutics, Inc. · TSX:GUD
Knight Therapeutics — Investor Presentation (August 2023)
20 slides from Knight Therapeutics's investor presentation, August 2023
Slide 1: Building a leading specialty pharmaceutical company
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation - Q2 2023 1 August 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated
Slide 3: Knight Overview
Knight Overview Knight is a multinational specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America • Since founding in February 2014 – Raised $685M at increasing valuations ($3.50 - $10.00) – Deployed or committed to deploy
Slide 4: Knight's Evolution
Knight’s Evolution 2011-2012 2013-2014 2015 2017 2019-2023 5 7 9 10 11 countries countries countries countries countries • Emerging specialty • Acquisition of • Expanded further • Moved HQ to • Acquisition by Knight player in the United Medical geographical Montevideo coverage (Bolivia and • Nov 201
Slide 5: Our Footprint
Our Footprint Revenue by Geography1 Over $326M in Revenue1 11 Countries + distributors in Central America and Caribbean ~ 700 Employees +100 Products Headcount by Geography2 +20 Partners Knight Affiliates Knight Distributors 3 Manufacturing Plants 1 R&D Center 1 Regional Distribution Center 1 Traili
Slide 6: Our Growth Strategies
Our Growth Strategies 1 In-license late-stage prescription pharmaceuticals Product 2 Acquire mature or “under-promoted” products from Big Pharma Portfolio 3 Develop near-term, low risk / low expense products Knight’s involvement Regulatory Market Sales and Discovery Pre Clinical Clinical Trials Appr
Slide 7: Product Portfolio
Our Market Pan-American (ex US) market represents ~6% of global pharmaceutical market Product Portfolio * Constant Dollar growth for all countries except Argentina. ** Brazil USD 28.7 bi excluding COVID vaccines. *** Exchange rates: BRZ 5.26, CHI, 912.87, COL 4812.49, ECU 1.0, MEX 19.67, PER 3.89, U
Slide 8: Our Portfolio
Our Portfolio PRODUCT PORTFOLIO1 KEY PRODUCTS Oncology and Hematology BERIATE® BGx 22% Innovative 78% Infectious Diseases REVENUE BY THERAPEUTIC AREA1 CNS AND Specialty 1 Trailing twelve months ending June 30, 2023, excluding impact of hyperinflation All dollar amounts herein are expressed in thousa
Slide 9: Product Pipeline
Product Pipeline Building for long-term growth, $50M - $75M peak potential sales 9
Slide 10: Our Partners
. Our Partners AstraZeneca? Ul) lh Bristol Myers Squibb” NOVARTIS (J GILEAD TherapeuticsMD ca, © Debiopharm Group @ m BELsINY 10
Slide 11: Financial Assets
Financial Assets Leveraging the balance sheet to source additional products and an attractive return • Secured loans to life-sciences companies: Nominal Loan Interest Product • Financing in exchange for product rights or Company Balance(1) Rate Maturity Rights pipeline assets Synergy US$7.5M 15.5% 2
Slide 12: Financial Highlights
Financial Highlights Key Promoted Products Driving Growth Knight acquires Biotoscana end of 2019 Note: Revenues exclude impact of hyperinflation/ IAS29 TTM 2023: Trailing twelve months ending June 30, 2023 All dollar amounts herein are expressed in thousands of Canadian dollars, unless otherwise ind
Slide 13: Financial Highlights
Financial Highlights Strong EBITDA and Operating Cash flows Knight acquires Biotoscana end of 2019 Note: Adjusted EBITDA is a non-GAAP measure and defined as operating income or loss adjusted to exclude amortization and depreciation, impairment of non-current assets, purchase price allocation accoun
Slide 14: Capital Allocation
Capital Allocation Over $200M invested in NCIB or 34% of shares outstanding* Knight acquires Biotoscana end of 2019 * Average buyback price to date - $5.83 All dollar amounts herein are expressed in thousands of Canadian dollars, unless otherwise indicated. All other currencies are in thousands. For
Slide 15: Financial Highlights
Financial Highlights Balance Sheet Highlights – June 30, 2023 Cash and Marketable Securities $141.6 million $1.32/share Financial Assets 1 $160.9 million $1.50/share Bank Loans $72.5 million $0.68/share Total Assets $1,013.7 million $9.46/share Net Asset Value $807.2 million $7.53/share Capital Stru
Slide 16: Management Team
Management Team Arvind Utchanah, CPA, CA - Uruguay Samira Sakhia - Canada Chief Financial Officer President and Chief Executive Officer Paladin Labs, Finance Paladin Labs, Chief Financial Officer Ernst & Young, Audit Executed sale of Paladin Labs for over C$3 billion Managed capital of $1 billion an
Slide 17: Board of Directors
Board of Directors Knight has a highly skilled and experienced Board of Directors 17
Slide 18: Key Achievements – last 12 months
Key Achievements – last 12 months Pipeline • Transferred MA of Exelon® across most countries • Submitted Tavalisse® (fostamatinib) in Colombia and Mexico • Submitted Pemazyre® (pemigatinib) in Argentina and Mexico • Submitted Minjuvi® (tafasitamab) in Mexico, Colombia and Argentina • Submitted Rembr
Slide 19: Why Knight?
Why Knight? Unique Platform in high growth Profitable Business with strong Strong Balance Sheet markets Revenues, Adj. EBITDA and Cashflow Revenues +19% vs PY Adj. EBITDA +20% vs PY Experienced Management Team Expanding Pipeline Strong Track Proven Record Diverse 19
Slide 20: Knight Therapeutics Inc. (TSX: GUD)
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation - Q2 2023 20 August 2023
Knight Therapeutics — Investor Presentation (August 2023) on 6ix